Acumen Pharmaceuticals Inc. (ABOS)
| Bid | 0.99 |
| Market Cap | 65.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.33M |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -0.64 |
| Forward PE | -0.67 |
| Analyst | Buy |
| Ask | 1.13 |
| Volume | 129,957 |
| Avg. Volume (20D) | 238,046 |
| Open | 1.10 |
| Previous Close | 1.10 |
| Day's Range | 1.06 - 1.10 |
| 52-Week Range | 0.85 - 3.92 |
| Beta | 0.10 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia....
Analyst Forecast
According to 3 analyst ratings, the average rating for ABOS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 542.79% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call TranscriptAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Office...